Foundayo vs Zepbound: Evidence and Administration (2026)
The FDA approved Foundayo (orforglipron) on April 1, 2026 as a once-daily oral option for chronic weight management in eligible adults. Zepbound (tirzepatide) is a once-weekly injectable dual GIP/GLP-1 agonist. ATTAIN-1 and SURMOUNT-1 were separate studies with different protocols; neither was a direct head-to-head comparison.
We may earn a commission through provider links. Matching affiliate offers and editorial priorities affect inclusion and suggested order in commercial guides. Scores are not clinical endorsements. Disclosure · Methodology
ATTAIN-1 studied once-daily orforglipron 6 mg, 12 mg, and 36 mg for 72 weeks in adults without diabetes. At 36 mg, mean body-weight change was −11.2% by the treatment-regimen estimand and −12.4% by the efficacy estimand. SURMOUNT-1 studied tirzepatide 15 mg for 72 weeks and reported −20.9% mean body-weight change.
Different trial populations, protocols, and estimands prevent these results from determining which medicine is better for an individual. This page does not verify Foundayo provider availability, cash prices, or insurance coverage; a licensed prescriber can discuss appropriate treatment options.
What the Studies Actually Show
This comparison uses separate pivotal trials: ATTAIN-1, NEJM 2025 for orforglipron and SURMOUNT-1, NEJM 2022 for tirzepatide. No direct head-to-head trial has been published.
| Endpoint | Foundayo (orforglipron) | Zepbound (tirzepatide) |
|---|---|---|
| Mean body-weight change (separate pivotal trials)1,2 | −11.2% (ATTAIN-1, 72 weeks, 36 mg; treatment-regimen estimand) Different trials, populations, and analysis plans; this is not a head-to-head comparison. | −20.9% (SURMOUNT-1, 72 weeks, 15 mg) |
| Administration | Once-daily oral pill; FDA label permits administration with or without food | Once-weekly subcutaneous injection |
| Mechanism | GLP-1 receptor agonist (small molecule) | Dual GIP/GLP-1 receptor agonist (peptide) |
| FDA approval for weight management | April 1, 2026 | November 2023 |
Who Should Choose Foundayo vs Zepbound
Choose Foundayo if…
- You'd rather take a daily pill than a weekly injection.
- You want the lowest-cost brand-name entry point: $149 a month to start and $299 at higher doses.
Choose Zepbound if…
- You want the larger average weight loss shown in tirzepatide's trials and don't mind injections.
- You have obstructive sleep apnea or Medicare: Zepbound KwikPen is covered by the Medicare GLP-1 Bridge for eligible people.
Monthly Cost Compared
| Foundayo (daily pill) | Zepbound (weekly injection) | |
|---|---|---|
| Starting doses | $149 (0.8 mg and 2.5 mg) | $299 (2.5 mg), $399 (5 mg) |
| Middle dose | $199 (5.5 mg) | $449 (7.5 mg, refilled within 45 days) |
| Maintenance | $299 (9 to 17.2 mg) | $449 (10 to 15 mg, refilled within 45 days); $699 if late |
| Approximate first year | $3,188 | $5,188 |
Self-pay prices from NovoCare and LillyDirect, checked October 21, 2026, assuming one month at each dose step. With commercial insurance that covers the drug, manufacturer savings programs can bring the cost to as little as $25 a month. A prescriber decides the dose schedule. Foundayo's 2.5 mg and 5.5 mg prices are temporarily reduced through December 31, 2026.
The Verdict
Foundayo and Zepbound have different routes of administration and were evaluated in separate trials. Their published results are not head-to-head evidence; treatment selection should be individualized with a licensed prescriber.
Frequently Asked Questions
How do ATTAIN-1 and SURMOUNT-1 results compare?
ATTAIN-1 reported −11.2% mean body-weight change at 72 weeks with orforglipron 36 mg by the treatment-regimen estimand (−12.4% by the efficacy estimand). SURMOUNT-1 reported −20.9% at 72 weeks with tirzepatide 15 mg. The studies had different designs and were not a direct head-to-head comparison.
Are Foundayo and Zepbound prices directly comparable?
This page does not verify Foundayo cash prices, provider availability, savings offers, or insurance coverage. Confirm current product, pharmacy, total cost, and coverage details directly with a licensed prescriber, dispensing pharmacy, and insurer.
Can I switch from Zepbound to Foundayo?
Switching between GLP-1 medications is a clinical decision. A licensed prescriber should assess indication, response, tolerability, contraindications, other medicines, and practical access before recommending a change.
- ATTAIN-1 — NEJM 2025 · Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025. ATTAIN-1, 72 weeks.
- SURMOUNT-1 — NEJM 2022 · Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022;387:205–216.
RxNotebook is an editorial publication, not a medical practice. We are not affiliated with the cited studies; source material does not endorse the providers shown. This is general information, not medical advice.